Search Results

Ipsen and Epizyme announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme).

Epizyme today reported second quarter 2022 financial results and provided a business update.

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update.

Epizyme, Inc. today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcare Conference.

Epizyme today reported first quarter 2022 financial results and provided a business update.

Epizyme today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, announced its participation in two investor conferences in March.

Regulatory News: Ipsen S.A. announced that Hibernia Merger Sub, Inc., its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Epizyme, Inc. at a price of $1.45 per share.

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference.